Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125328
Filing Date
2024-11-12
Accepted
2024-11-12 16:05:23
Documents
71
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q meip-20240930.htm   iXBRL 10-Q 1014607
2 EX-10.2 meip-ex10_2.htm EX-10.2 135843
3 EX-10.3 meip-ex10_3.htm EX-10.3 135277
4 EX-10.4 meip-ex10_4.htm EX-10.4 73489
5 EX-10.5 meip-ex10_5.htm EX-10.5 73236
6 EX-31.1 meip-ex31_1.htm EX-31.1 15862
7 EX-32.1 meip-ex32_1.htm EX-32.1 6840
8 GRAPHIC img104986740_0.jpg GRAPHIC 132946
  Complete submission text file 0000950170-24-125328.txt   6260435

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT meip-20240930.xsd EX-101.SCH 1146229
74 EXTRACTED XBRL INSTANCE DOCUMENT meip-20240930_htm.xml XML 698832
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Filer) CIK: 0001262104 (see all company filings)

EIN.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-41827 | Film No.: 241447959
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)